Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sarepta TherapeuticsLTS:0L35 -3.38%50 Days Inventory is 803.65 as of Mar. 2026, which is 8% below its 10-year median of 871.84. GuruFocus rates LTS:0L35 with a GF Score™ of 50/100 and a GF Value™ of $130.19 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 638 Biotechnology companies, Sarepta Therapeutics ranks worse than 80.09% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sarepta Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.11.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sarepta Therapeutics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.31.
Sarepta Therapeutics (LTS:0L35) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Sarepta Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sarepta Therapeutics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Sarepta Therapeutics Days Inventory Related Terms
Sarepta Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0L35 vs ZYME, BCAX, INVA: Days Inventory Comparison
For the Biotechnology subindustry, Sarepta Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics (LTS:0L35) has a Days Inventory of 803.65 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sarepta Therapeutics and its competitors. This is near median its historical median of 871.84. Over the past decade, Sarepta Therapeutics' Days Inventory has ranged from 361.85 to 46,304.41. According to the industry distribution chart, Sarepta Therapeutics ranks #511 out of 638 companies in the Biotechnology industry, placing it in the top 80.1%.
Is Sarepta Therapeutics' Days Inventory too high?
Sarepta Therapeutics' current Days Inventory of 803.65 is near median its 10-year median of 871.84. Over the past 10 years, this metric has ranged from a low of 361.85 to a high of 46,304.41. The Biotechnology industry median Days Inventory is 183.20. Sarepta Therapeutics' value of 803.65 is 338.7% above this industry median. Based on the distribution chart, Sarepta Therapeutics ranks #511 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sarepta Therapeutics has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Days Inventory compare to ZYME and BCAX?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #511 out of 638 companies for Days Inventory. This places Sarepta Therapeutics in the lower half of its industry. The industry median Days Inventory is 183.20. Sarepta Therapeutics' value of 803.65 is 338.7% above this benchmark. Historically, Sarepta Therapeutics' own Days Inventory has ranged from 361.85 to 46,304.41 over the past decade. While the company's 10-year median is 871.84 vs. the industry median of 183.20, Sarepta Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sarepta Therapeutics's current Days Inventory of 803.65 is 338.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sarepta Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sarepta Therapeutics's current Days Inventory is 803.65, which is near median its own 10-year median of 871.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $130.19, compared to a current price of $18.59 — trading 85.7% below its estimated fair value. The current Days Inventory is 803.65, which is near median its 10-year median of 871.84 and 338.7% above the Biotechnology industry median of 183.20. Sarepta Therapeutics' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current Days Inventory is 803.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of $18.59 is trading 85.7% below its estimated GF Value™ of $130.19.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0L35:
Days Inventory: 803.65 (near median its 10-year median of 871.84)
GF Value™: $130.19 vs. price of $18.59 (85.7% below fair value)
Industry Position: 338.7% above the Biotechnology median (#511 of 638)
No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
50GF Score
Get the complete analysis for LTS:0L35
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0L35 has been successfully added to your 
